Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 8/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 6/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | SELE | P16581 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26641352 | 0.80 | KDM4C (0.53) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL31607849 | 0.80 | KDM4C (0.53) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL3511939 | 0.80 | KDM4C (0.56) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL14875565 | 0.78 | KDM4C (0.57) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL4067951 | 0.77 | KDM4C (0.59) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL3511707 | 0.77 | NPC1 (0.53) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL3514416 | 0.77 | KDM4C (0.53) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL28935874 | 0.74 | KDM4C (0.65) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL2633488 | 0.72 | KDM4C (0.56) | KDM4CL3MBTL1NPC1RAB9AMEN1 | |
| SCHEMBL29447734 | 0.72 | KDM4C (0.53) | KDM4CL3MBTL1NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130102617-A1 | METHOD OF TREATING DIABETES, METABOLIC SYNDROME AND OBESITY USING PHENYLACETAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2013-04-25 | — | — | US | disclosed |
| US-20130102617-A1 | METHOD OF TREATING DIABETES, METABOLIC SYNDROME AND OBESITY USING PHENYLACETAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2013-04-25 | — | — | US | disclosed |
| US-20130102617-A1 | METHOD OF TREATING DIABETES, METABOLIC SYNDROME AND OBESITY USING PHENYLACETAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2013-04-25 | — | — | US | disclosed |
| US-8329707-B2 | Substituted pyrazine compounds | ASTELLAS PHARMA INC. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-8329707-B2 | Substituted pyrazine compounds | ASTELLAS PHARMA INC. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-8329707-B2 | Substituted pyrazine compounds | ASTELLAS PHARMA INC. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20100286171-A1 | PHENYLACETAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-11-11 | — | — | US | disclosed |
| US-20100286171-A1 | PHENYLACETAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-11-11 | — | — | US | disclosed |
| EP-2236498-A1 | PHENYL ACETAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-10-06 | — | — | EP | disclosed |
| EP-2236498-A1 | PHENYL ACETAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286171-A1 | PHENYLACETAMIDE DERIVATIVE | AADAC, PGC, PC | KDM4C 961/4885L3MBTL1 4317/4885NPC1 1244/4885 |
| US-20130102617-A1 | METHOD OF TREATING DIABETES, METABOLIC SYNDROME AND OBESITY USING PHENYLACETAMIDE DERIVATIVE | PC, PCK2, GCKR | KDM4C 2471/4885L3MBTL1 4654/4885NPC1 2338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.